Ships: within 1 business day
Bellido V et al. · Lancet (London, England) ·
The trial enrolled 1152 adults aged 18 and over with a BMI of 27 or higher and type 2 diabetes, all on stable treatment for their diabetes. Participants were randomly split into four groups of roughly equal size and given either placebo or GLP-3 R at one of three dose levels, by self-administered weekly injection, for 80 weeks. The main measurement was the percentage change in bodyweight from the start of the study to week 80, compared between each GLP-3 R group and placebo. The researchers also recorded adverse events and how many participants stopped treatment.
Compounds